Amgen’s KAI Deal Pays Off With Positive Phase III Trial Of Sensipar Successor
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug acquired for $315 million in cash from KAI in 2012 – AMG 416 – hits all primary and secondary endpoints in first pivotal study of hyperparathyroidism in dialysis patients; two other trials have yet to report.